- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04844138
Evaluating Overcoming Anxiety in Pregnancy and Postpartum as an Online Self-Directed Program
July 5, 2022 updated by: Kristin Reynolds, University of Manitoba
Evaluating a Self-Directed Cognitive Behavioural Therapy E-Health and M-Health Program for Anxiety in Pregnancy and Postpartum During COVID-19
The pregnancy and postpartum periods can be joyous times in life; however, they can also be filled with challenging physical, emotional, and lifestyle changes.
These changes may lead to feelings of stress, anxiety, and depression amongst new and expecting mothers, which can have negative effects on fetal and infant development (Beijers et al., 2010; Goodman et al., 2016).
The impacts of increased worry about health and safety due to COVID-19 as well as future-related uncertainties, paired with social (physical) distancing, may be felt especially strongly in this population.
Of concern, pregnant and postpartum women have low rates of mental health service use even prior to the pandemic (Fonseca et al., 2015).
E-health (Internet) and m-health (mobile application) psychological interventions are accessible, available at reduced cost, and can be accessed within users' homes, a factor that is particularly important during the pandemic (Andrews & Titov, 2010).
In this study, the investigators will disseminate a free, online, self-directed Cognitive Behavioural Therapy program to women experiencing symptoms of anxiety during pregnancy and postpartum.
This program has shown to be effective at improving symptoms of anxiety and depression when delivered in an in-person group format, and has high acceptability (Furer & Reynolds, 2015).
The investigators will transfer this program into an online format so that pregnant and postpartum users can navigate the sessions on their own, without the support of a clinician.
This program contains six modules which include topics such as coping with negative thoughts, unpacking the myth of the supermom, and managing expectations during pregnancy and postpartum.
Additionally, material related to COVID-19 has been added to the program to target any pandemic-related stress participants may be experiencing.
The investigators will collect information about the program's feasibility, acceptability, and effectiveness, which will inform future improvements to the program.
This program is expected to reduce participants' feelings of stress, anxiety, and depression, in addition to improving maternal attachment.
It is anticipated that these gains will be maintained when the investigators follow-up with participants one month after program completion.
This program has the potential to provide accessible and affordable mental health services to pregnant and postpartum women struggling during the pandemic.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
95
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3T 2N2
- University of Manitoba
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Currently pregnant or within 12 months postpartum
- Age 18 or older
- Experiencing symptoms of anxiety
- Have access to a computer, tablet, or smartphone
- Have access to the Internet
- Speak English
- Manitoba resident
- Willing to provide their name, email address, home address, and phone number
Exclusion Criteria:
- Current substance use disorder
- Diagnoses of bipolar disorder or schizophrenia
- Current suicidality
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Online Self-Directed Program
Participants in this condition will complete our six-week online self-directed program as soon as it's available.
|
The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format.
This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety.
Participants will complete six modules that will be released to them on a bi-weekly basis.
|
Other: Waitlist
Participants in this condition will receive treatment as usual for six weeks, after which point they will be invited to complete our online program.
|
The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format.
This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety.
Participants will complete six modules that will be released to them on a bi-weekly basis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Perinatal Anxiety Symptoms from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, and 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16. Both conditions will complete the short version weekly during the program.
|
To assess changes in perinatal anxiety symptoms throughout the study, the Perinatal Anxiety Screening Scale (PASS; Somerville et al., 2014) will be administered.
The PASS is a 31-item self-report measure assessing symptoms of anxiety during the perinatal period.
The scale has excellent reliability, adequate test-retest reliability, and strong evidence of convergent validity (Somerville et al., 2014).
A shortened version of the PASS will be administered to participants in both conditions when they are completing the online program.
This measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, and 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16. Both conditions will complete the short version weekly during the program.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Perinatal Depression Symptoms from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, and 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16. Both conditions will complete it weekly during the program.
|
To examine changes in perinatal depression symptoms throughout the study, the Edinburgh Postnatal Depression Scale (Cox et al., 1987) will be administered.
The EPDS is a 10-item self-report measure assessing symptoms of postnatal depression on a 0 to 4 scale.
Higher scores indicate higher levels of depression symptoms.
This scale exhibits satisfactory psychometric properties and is sensitive to change (Cox et al., 1987).
It has also been validated in pregnant populations.
The investigators have removed item 10 (suicidality measure) as participants with suicidal ideations will be screened out at the initial screening interview.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, and 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16. Both conditions will complete it weekly during the program.
|
Change in COVID-19 Stress from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
To assess changes in COVID-19 related stress, the COVID-19 Stress Scales (Taylor et al., 2020) will be administered.
This is a 36-item measure, with higher scores indicating higher levels of stress.
It measures specific factors that may contribute to pandemic-related distress, including danger and contamination fears, fears about the socio-economic consequences of the pandemic, xenophobia (i.e.
foreigners carrying the disease), compulsive checking and reassurance seeking, and traumatic stress symptoms about the virus.
When tested in a North American sample, these scales were found to be intercorrelated and had acceptable reliability and validity (Taylor et al., 2020).
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
Change in Non-Specific Psychological Distress from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12 and 16.
|
To assess changes in non-specific psychological distress across this study, the Kessler Distress Scale-Short Form-6-item version (K6; Kessler et al., 2002) will be administered.
The K6 is a 6-item self-report measure and has been shown to have excellent internal reliability.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12 and 16.
|
Change in Life Stress from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
To assess changes in life stress across this study, the Perceived Stress Scale (PSS; Cohen et al., 1983) will be administered.
The PSS is a 10-item self-report measure that assesses the extent to which one's life is appraised as stressful.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
Change in Maternal Antenatal Attachment from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
To evaluate changes in maternal antenatal attachment throughout this study, the Maternal Antenatal Attachment Scale (MAAS; Condon, 1993) will be administered to pregnant participants in both conditions.
The MAAS is a 15-item self-report measure that assesses maternal attachment towards an unborn baby in the antenatal period.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
Change in Maternal Postnatal Attachment from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
To evaluate changes in maternal antenatal attachment throughout this study, the Maternal Antenatal Postnatal Scale (MPAS; Condon & Corkindale, 1998) will be administered to postpartum participants in both conditions.
The MPAS is a 19-tem self-report measure that assesses maternal attachment towards an infant during the postnatal period.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
Change in Maternal Efficacy from Baseline
Time Frame: The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
To evaluate changes in maternal efficacy throughout this study, the Maternal Efficacy Questionnaire (MEQ; Teti & Gelfand, 1991) will be administered to postpartum participants in both conditions.
The MEQ is a 10-item self-report measure that assesses a mother's perception of her own parenting competence.
This outcome measure will help determine the effectiveness of this program.
|
The online self-directed program condition will complete it at weeks 1, 6, 10, while the waitlist condition will complete it at weeks 1, 6, 12, and 16.
|
Acceptability of the Online Self-Directed Program
Time Frame: The TAAS will be administered to the online self-directed program condition at week 2 and the waitlist condition at week 7.
|
To assess the acceptability of our online self-directed program, the Treatment Acceptability/Adherence Scale (TAAS; Milosevic et al., 2015) will be administered.
The TAAS is a self-report measure of treatment acceptability which exhibits sound psychometric properties.
The TAAS will be administered to participants in both conditions once they have completed the second module of the online program.
This measure will help determine the acceptability of this program with pregnant and postpartum persons.
|
The TAAS will be administered to the online self-directed program condition at week 2 and the waitlist condition at week 7.
|
Participant Satisfaction with the Online Self-Directed Program
Time Frame: This measure will be administered to the online self-directed program condition at program completion (week 6) and to the waitlist condition at program completion (week 12).
|
To assess participants' satisfaction with the Overcoming Anxiety in Pregnancy and Postpartum online self-directed program, the Treatment Satisfaction Measure (Furer & Reynolds, 2015) will be administered.
This measure was created for the Overcoming Anxiety in Pregnancy and Postpartum Group Treatment Program and has been adapted for this online program.
Two items ask about the helpfulness of the workbook and its focus on perinatal issues and are rated on a 5-point scale (i.e., from "very helpful" to "not at all helpful").
Two additional yes/no questions are included, regarding whether participants would recommend the program to other individuals in the perinatal period and whether they themselves would participate in the program again if needed.
Two final open-ended questions are included regarding what patients liked about the program, and any suggestions they would have for changes to it.
|
This measure will be administered to the online self-directed program condition at program completion (week 6) and to the waitlist condition at program completion (week 12).
|
Participant Experiences in the Online Self-Directed Program
Time Frame: The weekly feedback measure will be administered weekly during the program (online self-directed program condition: weeks 1-6; waitlist condition: weeks 6-12). The interview will take place at week 6.
|
To obtain more detailed feedback from participants about their experiences in this online program, the investigators have developed a weekly feedback measure.
This measure asks participants about their engagement with each module and allows them to provide specific feedback about the content of each module.
The investigators will also invite 25 participants from each condition to complete a qualitative interview to discuss their experiences in the program and on the waitlist for the program.
This will allow the investigators to collect more detailed data about what participants (dis)liked about the online program.
This data will allow the investigators to improve the program for future users.
|
The weekly feedback measure will be administered weekly during the program (online self-directed program condition: weeks 1-6; waitlist condition: weeks 6-12). The interview will take place at week 6.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kristin Reynolds, Ph.D., University of Manitoba
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57.
- Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002 Aug;32(6):959-76. doi: 10.1017/s0033291702006074.
- Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987 Jun;150:782-6. doi: 10.1192/bjp.150.6.782.
- Taylor S, Landry CA, Paluszek MM, Fergus TA, McKay D, Asmundson GJG. Development and initial validation of the COVID Stress Scales. J Anxiety Disord. 2020 May;72:102232. doi: 10.1016/j.janxdis.2020.102232. Epub 2020 May 4.
- Milosevic I, Levy HC, Alcolado GM, Radomsky AS. The Treatment Acceptability/Adherence Scale: Moving Beyond the Assessment of Treatment Effectiveness. Cogn Behav Ther. 2015;44(6):456-69. doi: 10.1080/16506073.2015.1053407. Epub 2015 Jun 19.
- Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005 Nov;106(5 Pt 1):1071-83. doi: 10.1097/01.AOG.0000183597.31630.db.
- Andrews G, Titov N. Is internet treatment for depressive and anxiety disorders ready for prime time? Med J Aust. 2010 Jun 7;192(S11):S45-7. doi: 10.5694/j.1326-5377.2010.tb03693.x.
- Beijers R, Jansen J, Riksen-Walraven M, de Weerth C. Maternal prenatal anxiety and stress predict infant illnesses and health complaints. Pediatrics. 2010 Aug;126(2):e401-9. doi: 10.1542/peds.2009-3226. Epub 2010 Jul 19.
- Condon JT. The assessment of antenatal emotional attachment: development of a questionnaire instrument. Br J Med Psychol. 1993 Jun;66 ( Pt 2):167-83. doi: 10.1111/j.2044-8341.1993.tb01739.x.
- Condon JT, Corkindale CJ. The assessment of parent-to-infant attachment: Development of a self-report questionnaire instrument. Journal of Reproductive and Infant Psychology. 1998; 16(1): 57-76.
- Fairbrother N, Janssen P, Antony MM, Tucker E, Young AH. Perinatal anxiety disorder prevalence and incidence. J Affect Disord. 2016 Aug;200:148-55. doi: 10.1016/j.jad.2015.12.082. Epub 2016 Apr 14.
- Fonseca A, Gorayeb R, Canavarro MC. Women׳s help-seeking behaviours for depressive symptoms during the perinatal period: Socio-demographic and clinical correlates and perceived barriers to seeking professional help. Midwifery. 2015 Dec;31(12):1177-85. doi: 10.1016/j.midw.2015.09.002. Epub 2015 Sep 21.
- Furer P, Reynolds K. Overcoming anxiety in pregnancy and postpartum. Unpublished treatment manual. Winnipeg, MB: University of Manitoba; 2015.
- Goodman JH, Watson GR, Stubbs B. Anxiety disorders in postpartum women: A systematic review and meta-analysis. J Affect Disord. 2016 Oct;203:292-331. doi: 10.1016/j.jad.2016.05.033. Epub 2016 Jun 1.
- Somerville S, Dedman K, Hagan R, Oxnam E, Wettinger M, Byrne S, Coo S, Doherty D, Page AC. The Perinatal Anxiety Screening Scale: development and preliminary validation. Arch Womens Ment Health. 2014 Oct;17(5):443-54. doi: 10.1007/s00737-014-0425-8. Epub 2014 Apr 4.
- Teti DM, Gelfand DM. Behavioral competence among mothers of infants in the first year: the mediational role of maternal self-efficacy. Child Dev. 1991 Oct;62(5):918-29. doi: 10.1111/j.1467-8624.1991.tb01580.x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 30, 2021
Primary Completion (Actual)
June 29, 2022
Study Completion (Actual)
June 29, 2022
Study Registration Dates
First Submitted
April 5, 2021
First Submitted That Met QC Criteria
April 8, 2021
First Posted (Actual)
April 14, 2021
Study Record Updates
Last Update Posted (Actual)
July 7, 2022
Last Update Submitted That Met QC Criteria
July 5, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P2020:104
- 53294 (Research Manitoba)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Perinatal Depression
-
Weill Medical College of Cornell UniversityRecruitingPerinatal Depression | Perinatal AnxietyUnited States
-
Sameera ShafiqNot yet recruitingPerinatal Depression | Perinatal AnxietyPakistan
-
Massachusetts General HospitalPositive Intelligence Inc.Not yet recruitingPerinatal Depression | Perinatal Anxiety
-
Children's National Research InstitutePatient-Centered Outcomes Research Institute; George Washington UniversityRecruitingPerinatal Depression | Prenatal Stress | Perinatal AnxietyUnited States
-
Oregon Health and Science UniversityNot yet recruitingPerinatal Depression
-
Northwestern UniversityNational Institute of Mental Health (NIMH); Palo Alto UniversityActive, not recruiting
-
Emory UniversityCompleted
-
Hamad Medical CorporationTerminatedSpecific Phobia | Perinatal Depression | Perinatal AnxietyQatar
-
IRCCS Centro San Giovanni di Dio FatebenefratelliRecruiting
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruiting
Clinical Trials on Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Enrolling by invitation
-
Children's Hospital of Fudan UniversityShanghai Simlab Health TechnologyRecruiting
-
American Board of Internal MedicineThe Josiah Macy, Jr. FoundationCompleted